The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 11 rounds in the feed, most often at Series D+ and in Biotech.
Venture capitalhbmhealthcare.comRounds from 2022-06-14 to 2026-10-28
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Dren Bio A privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases | Funding round Verified against 4 of 199 sources | $350M | 2026-10-28 | [ PART ] |
Crystalys Therapeutics Crystalystx develops therapeutics specifically for treating gout. | Series B |
| $130M |
| 2026-07-22 |
| [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ Verified against 1 of 6 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $67.4M | 2026-07-07 | [ PART ] |
CellCentric A drug-discovery platform | Series D Verified against 4 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $220M | 2026-05-06 | [ PART ] |
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus. | Series D+ Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | [ PART ] |
ELECTRA Therapeutics Electra Therapeutics develops SIRP-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $183M | 2025-10-22 | [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D+ Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $38M | 2025-05-22 | [ PART ] |
Curevo Curevo Inc. develops an adjuvanted subunit vaccine for the prevention of shingles in adults. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-03-17 | [ PART ] |
FORE Biotherapeutics A cancer therapeutics company developing targeted treatments for hard-to-treat tumours | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2023-08-23 | [ PART ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $168M | 2022-10-13 | [ PART ] |
Dren Bio A privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $65M | 2022-06-14 | [ LEAD ] |